Abstract
Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.
Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.
Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p
Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.
| Original language | English |
|---|---|
| Pages (from-to) | 105-113 |
| Number of pages | 9 |
| Journal | Journal of Nephrology |
| Volume | 28 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Ferric citrate
- Hemodialysis
- Iron metabolism
- Phosphate
ASJC Scopus subject areas
- Nephrology
Cite this
Effect of oral ferric citrate on serum phosphorus in hemodialysis patients : multicenter, randomized, double-blind, placebo-controlled study. / Lee, Chien Te; Wu, I. Wen; Chiang, Shou Shan; Peng, Yu Sen; Shu, Kuo Hsiung; Wu, Ming Ju; Wu, Mai Szu.
In: Journal of Nephrology, Vol. 28, No. 1, 2014, p. 105-113.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of oral ferric citrate on serum phosphorus in hemodialysis patients
T2 - multicenter, randomized, double-blind, placebo-controlled study
AU - Lee, Chien Te
AU - Wu, I. Wen
AU - Chiang, Shou Shan
AU - Peng, Yu Sen
AU - Shu, Kuo Hsiung
AU - Wu, Ming Ju
AU - Wu, Mai Szu
PY - 2014
Y1 - 2014
N2 - Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.
AB - Background: Hyperphosphatemia is a common complication in dialysis patients that can be treated by oral phosphate binders. We investigated the efficacy and safety of oral ferric citrate as a phosphate binder for Taiwanese patients with end stage renal disease and with hyperphosphatemia who were undergoing hemodialysis.Methods: This was a prospective, double-blind, placebo-controlled, randomized trial carried out in 5 hospitals in Taiwan. Ferric citrate (4 or 6 g/day) or placebo was administered for 56 days. Serum calcium, phosphorous levels, calcium × phosphorus product, serum ferritin level, transferrin saturation, and adverse events were recorded.Results: A total of 166 patients completed the trial. The placebo group had relatively constant serum data. Serum phosphorus declined significantly in the 6 g/day group (p Conclusions: A 56-day treatment with ferric citrate effectively controlled hyperphosphatemia and was well tolerated in maintenance hemodialysis patients. There were also moderate increases in serum ferritin and transferrin saturation.
KW - Ferric citrate
KW - Hemodialysis
KW - Iron metabolism
KW - Phosphate
UR - http://www.scopus.com/inward/record.url?scp=84922574601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922574601&partnerID=8YFLogxK
U2 - 10.1007/s40620-014-0108-6
DO - 10.1007/s40620-014-0108-6
M3 - Article
VL - 28
SP - 105
EP - 113
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 1
ER -